Toronto, ON and Tampa, FL – August 11, 2026 — DoseMe, a leading provider of clinical decision support technologies, today announced a partnership between Azar Lab and Firstline, a DoseMe company, to accelerate clinician access to the latest evidence-informed addiction medicine protocols directly at the point of care.
Azar Lab combines frontline clinical care with applied research, developing evidence-based protocols informed directly by real-world patient experience. The organization focuses on advancing practical approaches to addiction medicine, including tools and guidance that help clinicians more objectively assess opioid tolerance, initiate opioid agonist therapy more efficiently, and reduce avoidable withdrawal, treatment delays, and barriers to care.
The collaboration responds to growing demand from clinicians navigating increasingly complex substance use presentations, evolving withdrawal management challenges, and rapidly changing risks within the illicit drug supply. Through the partnership, Azar Lab’s clinical guidance protocols will be integrated into Firstline’s mobile clinical decision support platform, making the most current recommendations easier to access, update, and implement in real time.
Azar Lab’s protocols are already being used across hospitals, health systems, and clinical settings throughout North America, often extending far beyond their original institutional context. However, many clinicians continue to rely on older protocol versions circulated through static PDFs, institutional documents, or informal sharing networks that may not reflect the latest clinical refinements or emerging drug-supply realities.
“Clinicians are facing a rapidly evolving addiction and overdose landscape, yet many still lack easy access to practical, current bedside guidance,” said Dr. Pouya Azar, founder, Azar Lab. “Our goal is to help ensure that evidence-informed protocols can evolve as quickly as the clinical realities providers are encountering every day.” The partnership is particularly timely as healthcare providers across North America encounter increasing rates of fentanyl adulteration with animal sedatives and other emerging substances that can complicate withdrawal management, sedation, and treatment response. In many cases, limited published treatment pathways exist for these emerging toxidromes, creating a significant need for practical, rapidly deployable clinical guidance.
Azar Lab is actively developing updated and emerging protocols designed to support faster, safer, and more clinically responsive implementation, including guidance for increasingly complex withdrawal presentations linked to the evolving illicit drug supply. Firstline provides the digital delivery infrastructure that enables protocols to move beyond static documents into a searchable, mobile, continuously updated clinical support tool embedded directly into clinician workflows.
“Clinical knowledge in addiction medicine is evolving rapidly, but traditional methods of distributing protocols often cannot keep pace,” said Rick Malone, Vice President, Clinical and Science, Firstline + DoseMe. “This partnership helps bridge the gap between emerging evidence and bedside implementation by making trusted guidance more accessible, dynamic, and actionable for frontline clinicians.”
The collaboration reflects a broader shift toward integrating real-time clinical decision support, evolving evidence, and frontline usability to improve care delivery in addiction medicine and harm reduction settings.
Additional details regarding protocol availability, implementation timelines, and future clinical guidance initiatives will be announced in the coming months.
Additional Resources
About DoseMe
DoseMe is the provider of Firstline and DoseMeRx clinical decision support technologies that enable proactive, personalized care. Firstline is a mobile-first platform making treatment guidance accessible to every clinician, anywhere. DoseMeRx delivers clinically validated PK/PD models to individualize precision dosing in seconds. DoseMe’s evidence-based clinical intelligence helps reduce adverse drug events, antibiotic overuse, improved adherence to stewardship guidance, and provides clinicians a clear path to optimal care. For more information and real-world success stories, visit Success Stories